Short-term Bactericidal Effect of Contezolid in MAC-PD

Not Applicable

Not yet recruiting

• Conditions: Mycobacterium Avium Complex Pulmonary Disease
• Interventions: Drug: Contezolid; Drug: Azithromcyin; Drug: Rifampicin (RIF); Drug: Ethambutol

• Registration Number: NCT07084402
• Lead Sponsor: Bin Cao

Brief Summary

The goal of this clinical trial is to learn if contezolid works to treat mycobacterium avium complex pulmonary disease in adults. It will also learn about the safety of contezolid. The main questions it aims to answer are:

Does adding contezolid to standard regimen further decrease the bacterial load in patients' sputum compared with current standard regimen? What medical problems do participants have when taking contezolid along with standard regimen? Researchers will compare standard regimen plus contezolid to standard regimen alone to see if contezolid helps further lower the count of bacteria in patients' sputum.

Participants will:

Take contezolid and standard regimen (azithromycin, ethambutol and rifampicin) or standard regimen only for 6 months, contezolid is administered every day while other drugs are taken 3 times a week Visit the clinic once every 1 month for checkups and tests.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-07
• Study First Submitted: 2025-07-17
• Study First Submitted QC: 2025-07-17
• Last Update Submitted: 2025-07-17
• Study Start: 2025-07-24
• Study First Posted: 2025-07-24
• Last Update Posted: 2025-07-24
• Primary Completion: 2027-07-24
• Study Completion: 2027-12-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 188

Inclusion Criteria

1. Patients voluntarily participate in this study and sign the Informed Consent Form.

2. Age ≥ 18 years and ≤75 years; gender unrestricted.

3. Confirmed diagnosis of MAC pulmonary disease per ATS/IDSA 2020 guidelines or Chinese Guidelines for Diagnosis and Treatment of Nontuberculous Mycobacterial Diseases (2020 edition), with imaging features consistent with nodular bronchiectatic type.

4. No prior anti-MAC treatment within the 3 months preceding screening.

5. For premenopausal women of childbearing potential who are not surgically sterile:

   Must use a medically accepted contraceptive method (e.g., intrauterine device, hormonal contraception, or condom) during the study period and for 3 months following the last dose of investigational treatment.

   Serum or urine human chorionic gonadotropin (hCG) test must be negative within 72 hours prior to enrollment.

   Must not be breastfeeding. Male patients with partners of childbearing potential must use effective contraception during the study period and for 3 months after the last dose.

6. Organ function criteria met within one week prior to enrollment:

i. Hemoglobin ≥60 g/L; ii. Neutrophil count ≥0.5 × 10⁹/L; iii. Platelet count ≥60 × 10⁹/L; iv. Serum total bilirubin ≤3 × upper limit of normal (ULN); v. Aspartate aminotransferase (AST) ≤3 × ULN; vi. Alanine aminotransferase (ALT) ≤3 × ULN; vii. Serum creatinine <2 × ULN OR creatinine clearance ≥60 mL/min; viii. Blood urea nitrogen (BUN) ≤200 mg/L; ix. Urinalysis: Proteinuria <++; if proteinuria is +, 24-hour total protein must be <500 mg.

x. Fasting blood glucose within normal range OR stable glycemic control in diabetic patients.

xi. Cardiac function: No myocardial infarction in the preceding 6 months; No unstable angina or severe arrhythmias; New York Heart Association (NYHA) functional class >II.

Exclusion Criteria

1. History of allergy to any study drug in the treatment regimen.

2. Mixed infections with multiple mycobacteria, bacteria, fungi, or viruses (e.g., HIV coinfection).

3. Presence of congenital/acquired immunodeficiency disorders, active pulmonary malignancy (primary or metastatic), or other malignancies requiring chemotherapy/radiation therapy during the screening or study period.

4. History of solid organ transplantation.

5. Currently undergoing dialysis.

6. Uncontrolled radiation pneumonitis requiring steroid or immunoglobulin pulse therapy, active interstitial lung disease with clinical evidence, uncontrolled and significant pleural effusion or pericardial effusion.

7. Unstable systemic comorbidities including:

   Hypertensive crisis; Unstable angina; Congestive heart failure (NYHA Class III/IV); Myocardial infarction within the preceding 6 months; Severe psychiatric disorders requiring medication (e.g., schizophrenia, bipolar disorder); Severe hepatic or renal dysfunction (e.g., Child-Pugh Class C cirrhosis, eGFR <30 mL/min/1.73m²); Neurodegenerative diseases (e.g., Alzheimer's disease).

8. Poor gastrointestinal function or malabsorption syndrome.

9. Receipt of other investigational drugs within 4 weeks prior to the first study drug administration.

10. Concurrent participation in another interventional clinical trial, unless it is an observational/noninterventional study OR follow-up phase of a completed intervention trial.

11. Any physical examination findings or clinical tests deemed by the investigator as likely to:

Interfere with study results; Increase risks of complications during treatment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Contezolid plus standard regimen	Contezolid	Participants in this arm will receive contezolid 800mg po q12h, azithromycin 500mg po tiw (250mg po tiw if weight below 50kg), rifampicin 600mg po tiw and ethambutol 25mg/kg po tiw for 6 months.
Contezolid plus standard regimen	Azithromcyin	Participants in this arm will receive contezolid 800mg po q12h, azithromycin 500mg po tiw (250mg po tiw if weight below 50kg), rifampicin 600mg po tiw and ethambutol 25mg/kg po tiw for 6 months.
Contezolid plus standard regimen	Rifampicin (RIF)	Participants in this arm will receive contezolid 800mg po q12h, azithromycin 500mg po tiw (250mg po tiw if weight below 50kg), rifampicin 600mg po tiw and ethambutol 25mg/kg po tiw for 6 months.
Contezolid plus standard regimen	Ethambutol	Participants in this arm will receive contezolid 800mg po q12h, azithromycin 500mg po tiw (250mg po tiw if weight below 50kg), rifampicin 600mg po tiw and ethambutol 25mg/kg po tiw for 6 months.
Standard regimen	Azithromcyin	Participants in this arm will receive azithromycin 500mg po tiw (250mg po tiw if weight below 50kg), rifampicin 600mg po tiw and ethambutol 25mg/kg po tiw for 6 months.
Standard regimen	Rifampicin (RIF)	Participants in this arm will receive azithromycin 500mg po tiw (250mg po tiw if weight below 50kg), rifampicin 600mg po tiw and ethambutol 25mg/kg po tiw for 6 months.
Standard regimen	Ethambutol	Participants in this arm will receive azithromycin 500mg po tiw (250mg po tiw if weight below 50kg), rifampicin 600mg po tiw and ethambutol 25mg/kg po tiw for 6 months.

Primary Outcome Measures

Name	Time	Method
time-to-positivity of sputum mycobacterium culture	the end of month 3

Secondary Outcome Measures

Name	Time	Method
CT status of the lesion	at the end of month 3 and 6
culture conversion	at the end of month 3 and 6
time to first culture conversion	from enrollment to the end of month 6
adverse events	from enrollment to the end of month 6

Trial Locations

Locations (3)

Beijing Chest Hospital, Capital Medical University; 🇨🇳 Beijing, Beijing, China

China-Japan Friendship Hospital; 🇨🇳 Beijing, Beijing, China

Jiangxi Provincial Chest Hospital; 🇨🇳 Nanchang, Jiangxi, China